Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.

@article{Ide2006PeptideloadedDV,
  title={Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.},
  author={Fuyuaki Ide and Tetsuya Nakamura and Mariko Tomizawa and A I Kawana-Tachikawa and Takashi Odawara and Noriaki Hosoya and Aikichi Iwamoto},
  journal={Journal of medical virology},
  year={2006},
  volume={78 6},
  pages={711-8}
}
Immune response enhanced by therapeutic HIV-1 vaccine may control viral proliferation after discontinuation of highly active antiretroviral therapy (HAART). Although which strategies for therapeutic vaccination are feasible remains controversial, application of dendritic cells (DCs) as a vaccine adjuvant represents a promising approach to improving deteriorated immune function in HIV-1-infected individuals. The safety and efficacy of DC-based vaccine loaded with HIV-1-derived cytotoxic T… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

HIV-1 Latency

Current Topics in Microbiology and Immunology • 2018

Similar Papers

Loading similar papers…